

Long term β_2 -Agonists administration increases sprint performance in non- asthmatics

Merlini M¹, Whyte G², Chester N², Loosemore M³,
Marcora S¹, Dickinson J¹,

¹ Endurance Research Group University of Kent , ² RISES,
Liverpool John Moores University, ³ University College of London

AIM OF THE STUDY

Investigate the ergogenic effect of 5 weeks daily inhalation of long acting β_2 -Agonists on Sprint performance.

METHODS

Participants: 23 and 12 non asthmatic males and females

Design: Blind, Randomised, Counter balanced training study

Treatment groups:

- Salmeterol (SAL) 100 μ g (2 x 50 μ g twice daily) n=12
- Formoterol (FOR) 12 μ g (2 x 6 μ g twice daily) n=12
- Placebo (PLA) (2 x twice daily) n=11

30 mt Sprint

Strength and Power
Training

30 mt Sprint

Week 0




Week 6

Table 1: Change in 30 m sprint from week 0 to week 5

	Week 0	Week 5
SAL	7.38 ± 0.74 s	7.03 ± 0.72 s
FOR	7.10 ± 0.70 s	6.81 ± 0.74 s
PLA	7.40 ± 1.33s	7.40 ± 1.23 s

Figure 1: Change in 30 m sprint from week 0 to week 5



30m Sprint was greater 5 weeks post training in FOR (p=0.049) and SAL (p=0.040) compared to PLA.

CONCLUSION

- Sprint improvement observed over 5 weeks did not differ between SAL and FOR groups. However, FOR and SAL showed a significant improvement in sprint performance when compared with PLA following the 5 weeks of strength training.
- SAL and FOR may increased anaerobic ATP utilization, elevated glycolytic activity and enhanced rates of Ca^{2+} release and uptake from the sarcoplasmic reticulum.
- Future research should investigate potential mechanisms to explain our results.